<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01022060</url>
  </required_header>
  <id_info>
    <org_study_id>CAT-0913-CU</org_study_id>
    <nct_id>NCT01022060</nct_id>
  </id_info>
  <brief_title>Renalof in the Dissolution of Renal Calculi in Patients With Recurrent Calcic Lithiasis</brief_title>
  <official_title>Efficacy of Renalof in the Dissolution of Renal Calculi in Patients With Recurrent Calcic Lithiasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Catalysis SL</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Catalysis SL</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether Renalof administration promotes partial or
      total dissolution of urinary calculi and improves physicochemical parameters and metabolic
      activity in patients with recurrent calcic urolithiasis. The duration of this double-blind
      placebo controlled phase 3 clinical trial will be 12 weeks. The estimated number of patients
      to be recruited and randomized for the study is 110. Ultrasonographic and humoral parameters
      will be assessed every 4 weeks.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">February 2010</completion_date>
  <primary_completion_date type="Actual">February 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Size of calculi at week 12 (end of the treatment); week 0 refers to the beginning of treatment)</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of calculi at week 12 (end of the treatment); week 0 refers to the beginning of treatment</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Lithiasic activity at week 12 (end of the treatment); week 0 refers to the beginning of treatment</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Calciuria at week 12</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Uricosuria at week 12</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Uric acid at week 12</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxaluria at week 12</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Citraturia at week 12</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phosphatemia at week 12</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Calcemia at week 12</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total plasmatic calcium at week 12</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood ionic calcium at week 12</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Calcium Oxalate crystallization risk at week 12</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Calcium phosphate activity product at week 12</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Calcium Oxalate activity product at week 12</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pH of urine at week 12</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of adverse effects at any moment of treatment</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">110</enrollment>
  <condition>Recurrent Calcic Urolithiasis</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Renalof</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Renalof</intervention_name>
    <description>One Renalof tablet (Orally administered) three times a day (just before each meal: breakfast, lunch and dinner), for 12 weeks</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>One Placebo tablet (Orally administered) three time a day (just before each meal: breakfast, lunch and dinner), for 12 weeks</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Idiopathic calcic lithiasis

          -  Calculus size lesser than or equal to 2.0 cm (0.79 inches)

          -  Signed informed consent

        Exclusion Criteria:

          -  Calculus size greater than 2,0 cm (0.79 inches)

          -  Pregnancy

          -  Malignant neoplastic conditions

          -  Previous treatment for destruction of calculi in the urinary tract
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mirna Atiés Sánchez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute of Nephrology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institute of Nephrology</name>
      <address>
        <city>Havana City</city>
        <state>Havana</state>
        <zip>10400</zip>
        <country>Cuba</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Cuba</country>
  </location_countries>
  <verification_date>February 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 27, 2009</study_first_submitted>
  <study_first_submitted_qc>November 27, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 1, 2009</study_first_posted>
  <last_update_submitted>February 3, 2010</last_update_submitted>
  <last_update_submitted_qc>February 3, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 4, 2010</last_update_posted>
  <responsible_party>
    <name_title>Mirna Atiés Sánchez</name_title>
    <organization>Institute of Nephrology</organization>
  </responsible_party>
  <keyword>Dietary supplement</keyword>
  <keyword>Renalof</keyword>
  <keyword>Recurrent calcic urolithiasis</keyword>
  <keyword>Renal calculi</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calculi</mesh_term>
    <mesh_term>Urolithiasis</mesh_term>
    <mesh_term>Kidney Calculi</mesh_term>
    <mesh_term>Nephrolithiasis</mesh_term>
    <mesh_term>Lithiasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

